KLUS Pharma is the US subsidiary of Kelun-Biotech, a China-based corporation with a broad pipeline targeting unmet needs in oncology and other serious diseases. 

Our Company
City Skyline Across The Water

KLUS Pharma is based in Cranbury, NJ, and is the wholly-owned U.S. subsidiary of Kelun-Biotech, a corporation based in Chengdu, China. 

Image by Tim Bogdanov

We strive to discover and develop innovative biologics for the treatment of cancer and other serious diseases, addressing unmet needs and creating affordable medicines.

Image by Michael Longmire

We have a rich pipeline of small and large molecules targeting solid tumors and other indications with multiple ongoing clinical trials. 

Our Approach

Our antibodies undergo affinity maturation, humanization, and Fc engineering, generating lead candidates with optimal efficacy and safety.

bispecific antibodies 3.jpg

Our platform supports a wide variety of bispecific designs which allows for flexibility in selecting the optimal design based on intended MOA. 


Our third-generation ADC platform allows for site-specific conjugation of potent warheads to antibodies, with a variety of linkers and tunable DAR. 

May 29, 2022

Clinical updates will be presented at 2022 ASCO for the Phase 1 dose-expansion study of A166 in HER2+ metastatic breast cancer.

May 15, 2022

KLUS Pharma will attend 2022 BIO International in San Diego from June 13-16.

Mar 1, 2022

KLUS Pharma will attend BIO-Europe Spring to be held virtually from March 28-31, 2022.

Recent News